Doripenem

Doripenem
Brands

DEA Class; Rx

Common Brand Names; Doribax

  • Carbapenems

IV broad spectrum carbapenem antibiotic
For complicated intraabdominal and urinary tract infections in adults
Spectrum of activity similar to imipenem and meropenem but is more active in vitro against Pseudomonas aeruginosa

Indicated for the treatment of complicated intraabdominal infections.

For the treatment of complicated urinary tract infection (UTI), including pyelonephritis, and in patients with concurrent bacteremia.
For the treatment of sepsis.

Hypersensitivity to doripenem, beta-lactams or similar drugs

  • Headache (4-16%)
  • Nausea (4-12%)
  • Diarrhea (6-11%)
  • Anemia (2-10%)
  • Phlebitis (4-8%)
  • Rash (1-5%)
  • Pruritus (3%)
  • Transaminases elevated (1-2%)
  • Oral candidiasis (1%)
  • Renal impairment/failure (1%)
  • Anaphylaxis
  • Leukopenia
  • Neutropenia
  • Seizure
  • Thrombocytopenia
  • Toxic epidermal necrolysis, Stevens-Johnson Syndrome
  • Interstitial pneumonia
  • Renal impairment/failure

History of sensitivity to multiple allergens

May reduce serum valproic acid conc to subtherapeutic level: monitor levels frequently

Risk of Clostridium difficile-associated diarrhea on long-term use

Seizures reported with use

Not approved for ventilator-associated bacterial pneumonia (or any type of pneumonia); increased mortality when compared with imipenem/cilastatin (23% vs 16.7%); additionally, clinical response rates were lower with doripenem

Pregnancy Category: B

Lactation: unknown if excreted in breast milk; use caution

Adults

500 mg IV every 8 hours.

Elderly

500 mg IV every 8 hours.

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Doripenem

powder for injection

  • 500mg/vial
DrugsAce
Logo